OncologyTube

Can You Safely Skip Anthracycline in Early HR+ HER2- Breast Cancer?

New FLEX trial data answers the question clearly:

MammaPrint High Risk 2 + BluePrint Luminal B patients achieved 100% 3-year invasive disease-free survival with ACT versus only 89.3% with TC — delivering a 10.7% absolute iDFS benefit.

High Risk 1 patients did equally well with TC alone.

Dr. Joyce A. O’Shaughnessy, Principal Investigator of the FLEX study, breaks down exactly how MammaPrint + BluePrint now guide anthracycline decisions — and how the 2026 NCCN Guidelines have already incorporated these results.

Watch the full expert discussion and see how this changes daily practice:

https://oncologytube.com/mammaprint-blueprint-anthracycline-flex-study-nccn/

What are your thoughts on de-escalating anthracycline in High Risk 1 patients?

10.7% 3-yr iDFS Absolute Benefit with Anthracycline in MammaPrint High Risk 2 HR+/ HER2- Breast Cancer – FLEX Study Shows FLEX trial data: MammaPrint High Risk 2 + BluePrint Luminal B patients gain 10.7% absolute iDFS benefit with anthracycline (100% vs 89.3%). High Risk 1 do well with TC. NCCN 2026 update.

💡 What if one short course of a supplement found in strawberries could reverse frailty in breast cancer survivors after chemo?
New data from the TROFFI and PROFFI trials presented at MOASC 2026 says YES.
Dr. Mina Sedrak from UCLA shares groundbreaking research on how targeting therapy-induced senescence with the natural senolytic fisetin improved physical function, grip strength, and quality of life in survivors.
P16 biomarker clues, the 6-minute walk test as the key endpoint, and a bold new direction for survivorship care.
This could change everything for patients.
👉 Watch the full interview + read the complete article with slides:
https://oncologytube.com/can-fisetin-reverse-frailty-breast-cancer-survivors-moasc-2026
Tag a survivor or oncology friend who needs to see this! ❤️

Can Fisetin Reverse Frailty in Breast Cancer Survivors After Chemo? New Data from Dr. Mina Sedrak at MOASC 2026 New MOASC 2026 data: Fisetin can reverse frailty in breast cancer survivors. Dr. Mina Sedrak shares PROFY & TROPHY results on senescence.